Schatz Michael, Mosen David, Kosinski Mark, Vollmer William M, O'Connor Elizabeth, Cook E Francis, Zeiger Robert S
Department of Allergy, Kaiser Permanente Medical Center, San Diego, CA 92111, USA.
Qual Life Res. 2007 Mar;16(2):345-55. doi: 10.1007/s11136-006-9103-2. Epub 2006 Oct 11.
The Asthma Impact Survey (AIS-6) is a new six question asthma outcome tool for which information on validity has not been published.
To provide validation for the AIS-6 as a brief asthma-specific quality of life tool.
Surveys were sent to a random sample of members of a large managed care organization who were at least 35 years of age and in the two-year period preceding the survey had either (1) at least one documented asthma-related medical encounter, or (2) at least a 6 months supply of asthma medication dispensed. In addition to the AIS-6, the survey included a validated quality of life tool [the mini-Asthma Quality of Life Questionnaire (AQLQ)]; a validated asthma control questionnaire [the Asthma Therapy Assessment Questionnaire (ATAQ)]; a validated symptom severity scale (AOMS); and information regarding demographics, co-morbidities, asthma severity, and asthma management. The results of the AIS-6 were compared to the results of the other tools by means of correlation and factor analysis. Independent predictors of AIS-6 and AQLQ scores were determined by multiple stepwise linear regression analyses.
AIS-6 scores were significantly related to female sex, educational level, income, smoking, body mass index (BMI), COPD, steroid use, and hospitalization history in bivariate analyses. The AIS-6 score significantly correlated (r = - 0.84, p < 0.0001) with the AQLQ total score and loaded on the three factors (activity, symptoms, and concern/bother) reflected by the survey information and on which the AQLQ also loaded. Significant but somewhat smaller correlations were found between the AIS-6 and the ATAQ (r = 0.70, p < 0.0001) and the AOMS (r = 0.55, p < 0.0001). Independent predictors were the same for the AIS-6 and AQLQ and included oral steroid use, COPD history, BMI, female sex, educational level, and hospitalization in the past year.
These data support the validity of the short six-question AIS-6 as an asthma-specific quality of life tool.
哮喘影响调查（AIS - 6）是一种新的包含六个问题的哮喘结局工具，其有效性信息尚未发表。
验证AIS - 6作为一种简短的哮喘特异性生活质量工具的有效性。
向一个大型管理式医疗组织的成员随机抽样发送调查问卷，这些成员年龄至少35岁，且在调查前两年内，要么（1）至少有一次记录在案的与哮喘相关的医疗接触，要么（2）至少有6个月的哮喘药物配给量。除了AIS - 6，该调查还包括一个经过验证的生活质量工具[小型哮喘生活质量问卷（AQLQ）]；一个经过验证的哮喘控制问卷[哮喘治疗评估问卷（ATAQ）]；一个经过验证的症状严重程度量表（AOMS）；以及有关人口统计学、合并症、哮喘严重程度和哮喘管理的信息。通过相关性分析和因子分析将AIS - 6的结果与其他工具的结果进行比较。通过多元逐步线性回归分析确定AIS - 6和AQLQ分数的独立预测因素。
在双变量分析中，AIS - 6分数与女性性别、教育水平、收入、吸烟、体重指数（BMI）、慢性阻塞性肺疾病（COPD）、类固醇使用和住院史显著相关。AIS - 6分数与AQLQ总分显著相关（r = - 0.84，p < 0.0001），并加载在调查信息所反映的三个因子（活动、症状和担忧/困扰）上，AQLQ也加载在这三个因子上。在AIS - 6与ATAQ（r = 0.70，p < 0.0001）和AOMS（r = 0.55，p < 0.0001）之间发现了显著但稍小的相关性。AIS - 6和AQLQ的独立预测因素相同，包括口服类固醇使用、COPD病史、BMI、女性性别、教育水平和过去一年的住院情况。
这些数据支持简短的六个问题的AIS - 6作为哮喘特异性生活质量工具的有效性。
Zotero 插件